Our top pick for
Orgenesis Inc is a biotechnology business based in the US. Orgenesis shares (ORGS) are listed on the NASDAQ and all prices are listed in US Dollars. Orgenesis employs 309 staff and has a trailing 12-month revenue of around USD$35.8 million.
|Latest market close||USD$4.44|
|52-week range||USD$2.35 - USD$8.2|
|50-day moving average||USD$4.8411|
|200-day moving average||USD$5.6175|
|Wall St. target price||USD$10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$2.348|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-9.20%|
|1 month (2020-12-17)||-5.73%|
|3 months (2020-10-16)||-10.12%|
|6 months (2020-07-16)||-23.18%|
|1 year (2020-01-16)||-11.55%|
|2 years (2019-01-16)||-13.45%|
|3 years (2018-01-16)||6.4|
|5 years (2016-01-15)||1,245.45%|
Valuing Orgenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Orgenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Orgenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Orgenesis shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$35.8 million|
|Gross profit TTM||USD$15 million|
|Return on assets TTM||-15.09%|
|Return on equity TTM||0%|
|Market capitalisation||USD$110.4 million|
TTM: trailing 12 months
There are currently 381,977 Orgenesis shares held short by investors – that's known as Orgenesis's "short interest". This figure is 0.2% down from 382,727 last month.
There are a few different ways that this level of interest in shorting Orgenesis shares can be evaluated.
Orgenesis's "short interest ratio" (SIR) is the quantity of Orgenesis shares currently shorted divided by the average quantity of Orgenesis shares traded daily (recently around 33624.735915493). Orgenesis's SIR currently stands at 11.36. In other words for every 100,000 Orgenesis shares traded daily on the market, roughly 11360 shares are currently held short.
However Orgenesis's short interest can also be evaluated against the total number of Orgenesis shares, or, against the total number of tradable Orgenesis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orgenesis's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Orgenesis shares in existence, roughly 20 shares are currently held short) or 0.0172% of the tradable shares (for every 100,000 tradable Orgenesis shares, roughly 17 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Orgenesis.
Find out more about how you can short Orgenesis stock.
We're not expecting Orgenesis to pay a dividend over the next 12 months.
Orgenesis's shares were split on a 1:12 basis on 16 November 2017. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Orgenesis shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Orgenesis shares which in turn could have impacted Orgenesis's share price.
Over the last 12 months, Orgenesis's shares have ranged in value from as little as $2.35 up to $8.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orgenesis's is 1.3703. This would suggest that Orgenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Orgenesis Inc. offers biotechnology solutions focusing on cell and gene therapies (CGTs). The company's Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on identification of new therapies and leverages its POCare platform to provide a pathway for these therapies to treat patients. Additionally, the company's Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies. Orgenesis Inc. was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was founded in 2008 and is based in Germantown, Maryland.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.